Dashboard
Manage Tickers

GLMD


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

galmed-pharmaceuticals-reports-top-line-results-from-am-001-phase-1-bioavailability-study-demonstrating-enhanced-pharmacokinetic-profile-of-aramchol-meglumine-granules
Galmed Pharmaceuticals Reports Top-Line Re...
11/18/2025 13:44:46

The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher...

galmed-announces-top-line-results-from-am-001-study-of-aramchol-meglumine-showing-bioavailability-of-aramchol-meglumine-400mg-and-200mg-granules-is-higher-than-that-of-aramchol-free-acid-300mg-tablets
Galmed Announces Top Line Results From AM-...
11/18/2025 13:43:47

galmed-announces-top-line-results-from-am-001-study-of-aramchol-meglumine-showing-bioavailability-of-aramchol-meglumine-400mg-and-200mg-granules-is-hither-than-that-of-aramchol-free-acid-300mg-tablets
Galmed Announces Top Line Results From AM-...
11/18/2025 13:40:55

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/17/2025 21:07:48

galmed-announces-top-line-results-from-oncology-moa-studies-showing-combination-of-aramchol-stivarga-and-metformin-enhanced-gi-tumor-cells-killing-in-vivo-and-in-vitro
Galmed Announces Top-line Results From Onc...
11/17/2025 13:32:12

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
10/13/2025 21:06:47

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 12:08:21

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 21:06:02

galmed-pharmaceuticals-q2-eps-063-beats-083-estimate
Galmed Pharmaceuticals Q2 EPS $(0.63) Beat...
08/28/2025 13:36:46

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate o...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
08/28/2025 12:08:20

galmed-board-approves-digital-asset-management-strategy-including-potential-allocation-of-up-to-50-of-cash-reserves-to-be-used-for-digital-asset-purchases
Galmed Board Approves Digital Asset Manage...
08/25/2025 11:37:58

why-palo-alto-shares-are-trading-higher-by-around-7-here-are-20-stocks-moving-premarket
Why Palo Alto Shares Are Trading Higher By...
08/19/2025 12:01:09

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
06/20/2025 12:09:39

galmed-pharma-announces-discovery-of-proprietary-pd-blood-based-biomarker-signature-for-aramchol-clinically-advanced-stearoyl-coa-desaturase-1-inhibitor
Galmed Pharma Announces Discovery Of Propr...
05/27/2025 12:03:49

Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic ...

galmed-pharmaceuticals-q1-eps-062-beats-089-estimate
Galmed Pharmaceuticals Q1 EPS $(0.62) Beat...
05/22/2025 12:13:51

Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate o...

galmed-pharma-first-set-of-oncology-studies-show-aramchol-enhances-liver--colorectal-cancer-approved-therapeutic-regorafenib-effects-in-liver-and-colon-cancers-in-vitro-and-in-vivo-models
Galmed Pharma: First Set Of Oncology Studi...
05/06/2025 11:39:03

Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combinati...

crude-oil-down-2-roper-technologies-increases-2025-outlook
Crude Oil Down 2%; Roper Technologies Incr...
04/28/2025 16:38:56

dow-jumps-over-150-points-dominos-pizza-posts-upbeat-earnings
Dow Jumps Over 150 Points; Domino's Pizza ...
04/28/2025 13:56:16

galmed-pharmaceuticals--enters-sponsored-project-agreement-with-virginia-commonwealth-university-to-evaluate-aramchols-effect-on-overcoming-drug-resistance-in-gastrointestinal-cancers
Galmed Pharmaceuticals Enters Sponsored P...
04/17/2025 12:33:21

Galmed Pharmaceuticals (NASDAQ:GLMD) enters into a Sponsored Project Agreement with Virginia Commonwealth University (VCU) to e...

galmed-unveils-pharmacodynamic-blood-markers-for-aramchol
Galmed Unveils Pharmacodynamic Blood Marke...
04/15/2025 12:32:45

Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights int...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION